170 related articles for article (PubMed ID: 31012964)
1. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract][Full Text] [Related]
2. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
[TBL] [Abstract][Full Text] [Related]
3. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
5. TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.
Mattiske S; Ho K; Noll JE; Neilsen PM; Callen DF; Suetani RJ
Oncotarget; 2013 Nov; 4(11):1894-903. PubMed ID: 24177167
[TBL] [Abstract][Full Text] [Related]
6. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
7. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.
Dong P; Karaayvaz M; Jia N; Kaneuchi M; Hamada J; Watari H; Sudo S; Ju J; Sakuragi N
Oncogene; 2013 Jul; 32(27):3286-95. PubMed ID: 22847613
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
Song H; Wei M; Liu W; Shen S; Li J; Wang L
Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251
[TBL] [Abstract][Full Text] [Related]
12. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
John K; Alla V; Meier C; Pützer BM
Cell Death Differ; 2011 May; 18(5):874-86. PubMed ID: 21127500
[TBL] [Abstract][Full Text] [Related]
13. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
[TBL] [Abstract][Full Text] [Related]
14. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
Buckley NE; D'Costa Z; Kaminska M; Mullan PB
Cell Death Dis; 2014 Feb; 5(2):e1070. PubMed ID: 24556685
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.
Muller PA; Trinidad AG; Caswell PT; Norman JC; Vousden KH
J Biol Chem; 2014 Jan; 289(1):122-32. PubMed ID: 24220032
[TBL] [Abstract][Full Text] [Related]
17. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Cell Biochem Funct; 2018 Jun; 36(4):194-202. PubMed ID: 29653464
[TBL] [Abstract][Full Text] [Related]
19. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
